Alexandria Real Estate Equities is accepting applications for two $125,000 Alexandria LaunchLabs Innovation Prizes for entrepreneurs who can win support for their emerging businesses and a year’s worth of space at the Cambridge, MA, startup facility by showing what the urban life-sciences real estate investment trust says is excellence in early-stage science, leadership, and business strategy.
The uptake of continuous manufacturing, a faster and more flexible production process, has lagged in the risk-averse pharma and biotech industries.
Still, a number of the larger companies have dipped their toes in the water, including GlaxoSmithKline, Vertex, Johnson & Johnson and Eli Lilly. In addition to its collaboration with CPI, GlaxoSmithKline is working with the Center for Structured Organic Particulate Systems at Rutgers University to expand its knowledge of continuous manufacturing.
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the market average. Buying under-rated businesses is one path to excess returns. For example, long term QIAGEN N.V. (NYSE:QGEN) shareholders have enjoyed a 94% share price rise over the last half decade, well in excess of the market return of around 47% (not including dividends). On the other hand, the more recent gains haven’t been so impressive, with shareholders gaining just 27%.
The wisdom of Warren Buffett reflects a value-based philosophy about investing that says investors are buying shares in a business, and encourages strategic thinking about investment time horizon. Before placing a buy order for a stock, a great question we can ask is whether we would still be comfortable making the investment if we couldn’t sell it for many years?
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a late clinical-stage biopharmaceutical company focused on the global immunology market, today announced the appointment of Mr. Peter Greenleaf as Chief Executive Officer and as a Director on the Aurinia Board. The Company also announced the elevation of George M. Milne, Jr., Ph.D. to Chairman of the Board of Directors. Dr. Richard M. Glickman, who previously announced his plans to retire on November 6, 2018, will step down from his role as Chairman and CEO concurrent with Mr. Greenleaf’s appointment on April 29, 2019, and will remain an advisor to the Company for a period of 12 months.
The American Cancer Society has awarded three new grants to support and further cancer research in Maryland.
Each grant is funded for multiple years and together total nearly $2 million in cancer research funding. Since 1946, the society has awarded more than 1,091 grants to researchers in Maryland.
April 17, 2019 @ 4:30 PM – 7:00 PM
Join Mtech’s Biotechnology Research and Education Program (BREP) for a special launch event at the University of Maryland IBBR Building in Rockville on April 17th, 2019. Learn about this new industry-relevant new course and enjoy an evening of traditional BioBuzz networking with others in the regional biotech ecosystem.
The 5th annual Biohealth Capital Region (BHCR) Forum was held on April 8th and 9th at AstraZeneca in Gaithersburg, MD. Biotech and life science executives and expert speakers from industry, academia, healthcare, government, finance and real estate development, among others, converged to discuss the BHCR’s path forward to becoming a top three U.S. biotech cluster by 2023.
Rich Bendis, CEO of BioHealth Innovation, and host of the forum welcomed the 1,200 registered attendees (double the number of the first forum) with the annual update on the region’s progress towards that goal. After moving up one spot in 2018 to number four, according to GEN Biotechnology’s annual rankings, the BHCR is building momentum fueled by record VC investment, new lab space and multiple new companies moving into the region.
Baltimore is brimming with entrepreneurial talent. A new generation of CEOs and inventors are emerging right here in Baltimore with companies that are revolutionizing the life science & healthcare industries. The local community of universities and investors, coupled with the broader assets of the BioHealth Capital Region, has provided a lush ecosystem for innovators to take their ideas to the next level.
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office REIT uniquely focused on collaborative life science and technology campuses in AAA innovation clusters, today celebrates the inaugural member class of seed- and early-stage life science companies at the Alexandria LaunchLabs® – Cambridge with a highly curated Grand Opening event. The 20,000 RSF space, located at the Alexandria Center® at One Kendall Square, is now home to 13 new member companies rigorously selected from a deep pool of applicants based on the quality of their science, leadership teams and business strategies. Alexandria also offers a unique opportunity to access capital through the Alexandria Seed Capital Platform, which is led by Alexandria Venture Investments and supported by a preeminent group of member biopharmaceutical and venture entities. The Alexandria Seed Capital Platform recently closed on its first investment in a Cambridge‑based company.
